Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-11
2007-09-11
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S272000, C544S269000, C544S270000, C514S263220, C514S263230
Reexamination Certificate
active
10777849
ABSTRACT:
A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders:For example, a representative compound of the invention is:
REFERENCES:
patent: 5250534 (1993-10-01), Bell et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5321029 (1994-06-01), Maschler et al.
patent: 5346901 (1994-09-01), Bell et al.
patent: 5393755 (1995-02-01), Neustadt et al.
patent: 5409934 (1995-04-01), Smith et al.
patent: 5470579 (1995-11-01), Bonte et al.
patent: 5637593 (1997-06-01), Porter et al.
patent: 5688768 (1997-11-01), Coughlin et al.
patent: 5719283 (1998-02-01), Bell et al.
patent: 5759994 (1998-06-01), Coughlin et al.
patent: 5798248 (1998-08-01), Coughlin et al.
patent: 5824683 (1998-10-01), McKittrick et al.
patent: 5856448 (1999-01-01), Coughlin
patent: 5859006 (1999-01-01), Daugan
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5877216 (1999-03-01), Place et al.
patent: 5939419 (1999-08-01), Tulshian et al.
patent: 5955611 (1999-09-01), Dunn et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 5981527 (1999-11-01), Daugan et al.
patent: 5981563 (1999-11-01), Lowrey
patent: 6023640 (2000-02-01), Ross
patent: 6024936 (2000-02-01), Coughlin et al.
patent: 6025494 (2000-02-01), Daugan
patent: 6037346 (2000-03-01), Doherty, Jr. et al.
patent: 6051594 (2000-04-01), Lowrey
patent: 6066735 (2000-05-01), Dunn et al.
patent: 6087362 (2000-07-01), El-Rashidy
patent: 6100270 (2000-08-01), Campbell
patent: 6124101 (2000-09-01), Coughlin
patent: 6140329 (2000-10-01), Daugan
patent: 6143746 (2000-11-01), Daugan et al.
patent: 6197541 (2001-03-01), Coughlin
patent: 6362178 (2002-03-01), Niewöhner et al.
patent: 6403597 (2002-06-01), Wilson et al.
patent: 6469012 (2002-10-01), Ellis et al.
patent: 6469016 (2002-10-01), Place et al.
patent: 6472434 (2002-10-01), Place et al.
patent: 6512002 (2003-01-01), Lee et al.
patent: 6821978 (2004-11-01), Chackalamannil et al.
patent: 2002/0198205 (2002-12-01), Himmelsbach et al.
patent: 2003/0199528 (2003-10-01), Kanstrup et al.
patent: 2003/0232845 (2003-12-01), Dahanukar at al.
patent: 2003/0232987 (2003-12-01), Dahanukar et al.
patent: 2004/0077645 (2004-04-01), Himmelsbach et al.
patent: 2006/0205711 (2006-09-01), Himmelsbach et al.
patent: P 19 38 016.6 (1971-01-01), None
patent: 0 258 191 (1988-03-01), None
patent: 0 389 282 (1990-09-01), None
patent: 0 389 282 (1990-09-01), None
patent: 0 389282 (1990-09-01), None
patent: 389282 (1990-09-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0 526 004 (1993-02-01), None
patent: 0 702 555 (1996-03-01), None
patent: 2.116.302 (1972-07-01), None
patent: 89/10123 (1989-11-01), None
patent: WO91/07945 (1991-06-01), None
patent: WO91/07945 (1991-06-01), None
patent: 91/19717 (1991-12-01), None
patent: WO91/19717 (1991-12-01), None
patent: 92/05175 (1992-04-01), None
patent: 92/05176 (1992-04-01), None
patent: WO92/05175 (1992-04-01), None
patent: WO92/05176 (1992-04-01), None
patent: WO99/54331 (1992-04-01), None
patent: WO 92/11260 (1992-07-01), None
patent: WO92/11260 (1992-07-01), None
patent: 93/23401 (1993-11-01), None
patent: WO93/23401 (1993-11-01), None
patent: 94/19351 (1994-09-01), None
patent: WO94/28902 (1994-12-01), None
patent: 96/16644 (1996-06-01), None
patent: 96/16657 (1996-06-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/03985 (1997-02-01), None
patent: 97/24334 (1997-07-01), None
patent: 97/43287 (1997-11-01), None
patent: 98/08848 (1998-03-01), None
patent: 98/15530 (1998-04-01), None
patent: 98/38168 (1998-09-01), None
patent: 98/49166 (1998-11-01), None
patent: 99/00359 (1999-01-01), None
patent: 99/00373 (1999-01-01), None
patent: 99/21558 (1999-05-01), None
patent: 99/21831 (1999-05-01), None
patent: WO99/24433 (1999-05-01), None
patent: 99/42452 (1999-09-01), None
patent: 99/43674 (1999-09-01), None
patent: 99/43679 (1999-09-01), None
patent: 99/54333 (1999-10-01), None
patent: WO99/54331 (1999-10-01), None
patent: WO99/62905 (1999-12-01), None
Ho-Sam Ahn et al, “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE6 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”,J. Med. Chem. , vol. 40, No. 14, pp. 2196-2210 (1997).
J.L. Ambrus et al, “Studies on Vasoocclusive Crisis of Sickle Cell Disease. I. Effect of Pentoxifylline”Journal of Medicine, vol. 10, No. 6, pp. 445-456 (1979).
Bradley D. Anderson et al, “Preparation of Water-Soluble Compounds Through Salt Formation”, The Practice of Medicinal Chemistry, C. G. Wermuth, Ed.,Academic PressNew York. pp. 739-754 (1996).
M.I. Argel et al, “Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein Kinase Activity and Cyclic Nucleotide Levels” ,J. Mol. Cell Cardiol, vol. 12, No. 10, pp. 939-954, Abstract (1980).
Hans-Joachim Arnold et al, “Pharmacopoeia of Traditional Medicine In Venda”,Journal of Ethnopharmacology, vol. 12, pp. 35-74 (1984).
William J. Aronson et al., “The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide”,The Journal of Urology, vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).
Joseph A. Beavo, “Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms”,Physiological Reviews, vol. 75, No. 5, pp. 725-748 (Oct. 1995).
Joseph A. Beavo & David H. Reifsnyder, “Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors”,Trends in Pharmacological Sciences, vol. 11, No. 4, pp. 150-155 (Apr. 1990).
Stephen M. Berge et al, “Pharmaceutical Salts”,J. Pharmaceutical Sciences, Am. Pharm. Assoc. and Pergamon Press, vol. 66, No. 1, pp. 1-19 (Jan. 1977).
Anne Bowman et al, “Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle”,Br. J. Pharmac., vol. 81, pp. 665-674 (1984).
V. Mirone et al, letter to ed. re. “Intracavernous Cyclic GMP Products Produces Penile Erection in Patients with Erectile Dysfunction”,British Journal of Urology, vol. 71, No. 3, p. 365 (March 1993).
Gary Brooker et al, “Radioimmunoassay of Cyclic AMP and Cyclic GMP”,Advances in Cyclic Nucleotide Research, Paul Greengard et al, Eds., vol. 10, pp. 1-33 (1979).
Margaret Ann Bush, “The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of corpus cavernosum smooth muscle”,Ph.D. dissertation U.C.L.A.(UMI Dissertation Services Order No. 9319914) (179 pgs) (1993).
Peggy Bush et al, “Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum”,Journal of Urology, vol. 147, pp. 1650-1655 (Jun. 1992).
S. Carrier et al, “Erectile Dysfunction,”Endocrinology and Metabolism Clinics of North America: Clinical Andrology, vol. 23, No. 4, pp. 773-782 (Dec. 1994).
P. Cazzulani et al, “Pharmacological Activities of the Main Metabolite of Flavoxate 3- Methylflavone-8-carboxylic Acid”,Drug. Res. , vol. 38 (1), No. 3, pp. 379-382 (1988).
J. Cortijo et al, “Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including Studies with Human Bronchus”,Br. J. Pharmacol., vol. 108, pp. 562-568 (1993).
Jacob de Boer et al., “Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors”,Br. J. Pharmacol., vol. 106, pp. 1028-1034 (1992).
Dario Doller et al., “The GIF System as a Tool in Medicinal Chemistry: The Oxidation of SCH57726 under GOAGG III Conditions”,Bioorganic and Medicinal Chemistry Letters, vol. 7, No. 11, pp. 1381-6 (1997).
Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase Inhibitor E4021 Dilates the Pulmonary Circulation.American Journal Respir. Crit. Care Med., vol. 160:858-865.
I.J. Fishman, “Treating Erectile Dysfunction: New Approaches”,Drug Therapy, vol. 8, pp. 102-110 (Aug. 1989).
Gaine S.P.
Boyle Craig
Chackalamannil Samuel
Stamford Andrew
Wang Yuguang
Berch Mark L.
Russell Mark W.
Schering Corporation
LandOfFree
Xanthine phosphodiesterase V inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Xanthine phosphodiesterase V inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthine phosphodiesterase V inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3758769